Bounce Mobile Systems Inc (PK) (BNCM) Cotización

Very bright future ahead here

$BNCM - Nice day!

600K going to be sorry he sold

BNCM on the move 60% and not even a milly volume we get 10 milly volume and we see dimes for sure

keep on slappen.....financials will be to the moon !!!!!!!! solid company with great history and a bright future.

Audited financials incoming

Take off, just as I said. Once this moves up to OTCQB you won't be able to get in below .15

keep on buying !!!!!!!!

Looks like word is getting out about the realities here. Strong fundamentals don't lie

more and more activity is a good thing

BNCM is a relatively safe bet (pharmaceuticals in an expanding economy) in an otherwise chaotic and stagnant world.

BNCM could be a game-changer!

Anyone can contact the company themselves and ask about the audited financials; they're coming. Once it uplists, you'll see this in the .10 - .15 range.

+63 949 993 5537
info@bncm.net

Last chance to load at these levels imo

people just need to slap it a little harder tomorrow ..get that pps up

nice trading day for sure ...we all need a little love

Pharma Market is booming there and everywhere..⚕️💊

It's going to shoot up out of nowhere one day, and the vultures here will be left buying shares at .04 and .05, if they're lucky

You can always tell a midwit by the way he bashes BNCM - a company that has done nothing but follow an honest trajectory.

Uplist to OTCQB this year, followed by restructuring favorable to shareholders. Very simple.

Should not have bought at all; or alternatively, dumped earlier.

BNCM getting some luv on ask today

Humbert ...your scaring me with " next year uplist " we better get fin by end of march as promised and hopefully up list within A FEW MONTHS. Come Delex let get the ball rolling !!!!!!!!!!!!!!

Confirmed the company will uplist to OTCQB this year; all it requires is a little patience to make bank here

When the audited financials hit this spring, she'll shoot up, and probably before then.

SERVICE PROVIDERS
Securities Counsel
Vic Devlaeminck PC
10013 N.E. Hazel Dell Avenue
Suite 317
Vancouver, WA 98685

Interesting to see how BNCM is aligning with broader market trends 📈

Should've waited, sorry

I did regret it. That is why I sold.

most positive (buys) in months today

u know we can all see ur post history u called PayPal a scam a few weeks ago, makes me feel pretty secure here BNCM

Hahaha, imagine being this much of a loser.

HITMAN970 again....... list where you have info on fraud or else leave post it so we can verify !!!

And you are in breach of Federal securities laws for pumping and conspiring to defraud BNCM rookies

I was able to, and the problem may be on your end.

You can contact BNCM's management here:

www.bncm.net
+63 949 993 5537
info@bncm.net

Humbert I tried to email Delex but could not finish the email due to the "i am not a robot " would not let me submit , have you emailed Delex before ?

Hitman is a basher - that's all.

Hitman970 where do I go to get this information about fraud ??

Wow, the market is reacting to BNCM today!

All it means is that someone made two accounts.

In truth, I've never seen a company with facts that are easier to verify on this website; Delex is the real deal, as everyone can plainly see.

DELEX has 30 FDA Approved Products

Companies like BNCM actually do wonders for the reputation of the Pink tier, which is filled to the brim with highly questionable operations. With Delex, you see a company using the OTC system in a responsible, dignified manner.

Admin speaks the truth LMFAO.
BNCM/Delex will never go anywhere because it doesn't exist.

@straightlines STOP OPENING NEW ACCOUNTS - if you continue it's likely you'll get this board closed to posting due to manipulation.

PD94 ...how did you hear about Delex

Wow! And, it is trading under a penny?

Wow! DELEX has 700 hospitals and pharmacy clients!

BNCM and DELEX unveils Roadmap to Drive Innovation, Growth and Market Leadership in the Healthcare Sector.
Press Release | 02/26/2025


For 15 years, DELEX Pharma has been a leading force in the Philippine healthcare sector, consistently delivering high-quality pharmaceutical products and building a reputation for excellence. With its impressive history, extensive product offerings, and visionary expansion strategies, DELEX is poised for unprecedented growth.


Here's a closer look at DELEX ROADMAP, based on its strengths and strategic plans designed to propel its success well into the future and drive innovation, growth, market leadership in the healthcare sector.


15 Years of Robust Business Growth
DELEX Pharmas legacy is built on 15 years of sustained growth, ranking as the third-largest national player in the hospital channel market according to IQVIA. The companys leadership team, with over three decades of experience in the healthcare sector, has played an integral role in driving this growth and positioning DELEX as a powerhouse within the industry.


Leadership That Drives Excellence
At the helm of DELEX is a group of seasoned leaders with extensive experience in both the pharmaceutical and medical industries. Their entrepreneurial acumen and expertise, honed through years of working with multinational healthcare giants, empower DELEX to continually adapt and thrive in a competitive market. This leadership ensures the companys future success as they continue to execute on their ambitious vision for the future.


Holder of Various FDA Business Licenses & Permits
From importing and distributing pharmaceutical products to running drugstores and medical devices, DELEX is fully equipped to meet the regulatory standards that govern the diverse landscape of the Philippine healthcare industry. DELEX Pharma currently holds various licenses and permits issued by the Philippines Food and Drug administration for (i) Importer/ Wholesaler/Distributor of Drugs (ii) Importer of Medical Devices (iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler and (v) Drugstore Operator, including Online Order and Delivery.


Holder of 30 FDA Approved Hospital Products
DELEX Pharma is committed to continuously expanding its product portfolio to meet the needs of both healthcare professionals and patients. With over 30 FDA-approved hospital products and numerous medical device products, DELEX is pushing the boundaries of innovation. The companys recent launch of 11 new pharmaceutical products and strategic partnerships with multinational medical device firms demonstrates its aggressive expansion strategy across multiple therapeutic and diagnostic areas.


Expanding the Distribution Channels
With a network that already supplies nearly 700 hospitals nationwide and has established a foothold in over 900 Mercury Drug branches, DELEX is positioned for even greater reach. By building on its strong distribution network and forming strategic partnerships with healthcare providers, DELEX aims to expand its footprint, enhancing its market development and creating integrated healthcare solutions to improve patient outcomes.


Expanding the Medical Device Business
The medical device market in the Philippines is experiencing rapid growth, and DELEX is well-positioned to capitalize on this opportunity. With a strategic alliance with leading international companies such as Amsino, Masimo, and Verathon, DELEX aims to be a key player in the medical device sector. These collaborations will not only enhance DELEXs offerings but also solidify its position as a leading distributor of high-quality healthcare solutions.


Expanding the Pharmacy Stores
Building on the success of its first pharmacy branch opened in 2021, DELEX plans to expand its retail pharmacy business to 60 locations in the coming years. This expansion comes at a time when the pharmacy market is poised for significant growth, driven by increased demand for pharmaceutical services and products. DELEXs strategy of situating drugstores near hospitals and high-traffic areas is a smart move to generate strong sales and meet the needs of the community.


Expanding the Online Pharmacy Business
As the healthcare landscape becomes increasingly digital, DELEX is tapping into the rapidly growing ePharmacy market. Through its online platform, DELEX offers a seamless 24/7 ordering and delivery service for a wide range of over-the-counter medicines, prescription drugs, and health products. As the Philippines ePharmacy market continues to expand, DELEX is set to capture a broad customer base and meet the demand for convenient, cost-effective healthcare solutions.


Expand DELEXs Training Programs and Global Networks
DELEX has proven its commitment to improving healthcare outcomes through educational initiatives such as the DELEX ICU Forum. What began as an in-person event has grown into a powerful online platform that has attracted nearly 200,000 healthcare professionals worldwide. The forum facilitates important conversations on critical care advancements, treatment protocols, and best practices, further solidifying DELEXs role as a thought leader in the healthcare space.


Strategic Acquisition to Expand DELEXs Product Portfolio
In 2022, DELEX Pharma made a significant move to acquire JMN Brothers Pharma Limited, a company known for its expertise in womens health and beauty. This acquisition enables DELEX to expand its hospital product portfolio and tap into new market segments, further diversifying its offerings and increasing its market share in the healthcare sector.


Commitment to Quality Through ISO Certification
DELEX Pharmas commitment to quality and operational excellence has been recognized globally. The company recently underwent and passed the ISO 9001:2015 re-certification, underscoring its dedication to meeting international quality standards and providing superior products and services to its customers.


Strong Distribution and Warehouse Capabilities
With a robust infrastructure that includes a dedicated trade sales team and state-of-the-art SAP ERP systems, DELEX Pharma ensures efficient distribution and inventory management. This operational efficiency allows DELEX to respond promptly to customer demands and maintain high levels of service across its entire distribution network.


Winner of Several Industry Awards
DELEXs track record of success is reflected in the numerous accolades and awards the company has received. These include recognition as the Diversity Company of the Year and SME Company of the Year by the Asia CEO Awards, as well as individual honors for its leadership team. These awards affirm DELEXs position as a top-tier healthcare company in the Philippines.


Asias Booming Pharmaceutical Market
With the Asian pharmaceutical market projected to reach US$304.8 billion by 2029, DELEX Pharma is poised to play a key role in this rapidly growing industry. The companys strategic positioning and expansive product offerings give it a competitive edge as the market continues to grow at a steady pace.


Name Change and Ticker Symbol
A formal application to rename BNCM to DELEX and update the ticker symbol will be applied from Q1 2025, aligning with the new direction of the merged company. This rebrand reflects the companys ambition to further solidify its presence in the global healthcare market and prepare for an exciting phase of expansion.


Regulation A Filing and SEC Approval
To support its future growth, DELEX Pharma plans to file for Regulation A with the SEC from March 2025, opening up new avenues for investment and funding. This filing is a crucial step in DELEXs journey toward achieving its long-term business objectives.


Uplist to OTCQB and NASDAQ
DELEX plans to take its corporate visibility to the next level by applying for an uplist to the OTCQB in 2025, with the ultimate goal of listing on the NASDAQ. This move will open the doors for increased capital access and heighten DELEXs visibility among global investors.



DELEX Pharma: A Future of Growth and Innovation

With a proven track record of success, a visionary leadership team, and a strategic expansion plan that spans multiple facets of the healthcare industry, DELEX Pharma is poised to become a dominant player in the global healthcare market. As the company continues to innovate, expand, and strengthen its presence in key sectors, it remains on track to achieve its ambitious goals and deliver value to its stakeholders. The future of DELEX Pharma looks brighter than ever, and investors have a unique opportunity to be part of this dynamic journey.

For more information, visit - https://bncm.net/

I don't understand why some bashers can't understand Delex is a profitable company that has revs of almost 900k a month with increases month by month ....most pinks don't even come close to these standards and just offer bs hot air???

lol......I've scooped up your shares and then some. $BNCM

I'm sorry, but you'll come to regret this. This is the best time to load if there ever was one